Talk:Pexastimogene devacirepvec

We should probably move/rename this to Pexa-vec soon
Pexa-vec ? or would pexastimogene devacirepvec be the INN ? - Rod57 (talk) 09:35, 10 May 2013 (UTC)


 * You are right, this page will need moving to pexastimogene devacirepvec, can create a redirect to there from Pexa-vec, this would be in-keeping with talimogene laherparepvec. Viraltonic (talk) 11:12, 10 May 2013 (UTC)
 * ✅ - Rod57 (talk) 18:45, 14 October 2016 (UTC)

Out of date
Article gives status as of Aug 2011 but the phase III trial failed its primary endpoint in 2013 and the company website gives the March 2014 development plan. - Rod57 (talk) 23:04, 14 November 2014 (UTC)
 * Website also says "A Phase 2b study (TRAVERSE) was also initiated in HCC patients whose disease had progressed on or following treatment with sorafenib or who could not tolerate that treatment. In September 2013, Transgene announced that the TRAVERSE study did not meet its primary endpoint of overall survival in this challenging-to-treat patient population. Therefore, Pexa-Vec will not be further developed as a second-line treatment for HCC but only in the first-line indication." - Rod57 (talk) 18:55, 14 October 2016 (UTC)

RR gene also deleted
The ribonucleotide reductase gene (aka RNR) may also be deleted - implied by Oct2016 ref, but not mentioned by Cripe2015. - Rod57 (talk) 18:47, 14 October 2016 (UTC)